TY - JOUR
T1 - A meta-analysis of the global impact of the COVID-19 pandemic on stroke care & the Houston Experience
AU - Reddy, Sujan T.
AU - Satani, Nikunj
AU - Beauchamp, Jennifer E.S.
AU - Selvaraj, Sudhakar
AU - Rajan, Suja S.
AU - Rahbar, Mohammad H.
AU - Tahanan, Amirali
AU - Kim, Sori
AU - Holder, Travis
AU - Jiang, Xiaoqian
AU - Chen, Luyao
AU - Kamal, Haris
AU - Indupuru, Hari Kishan R.
AU - Wu, Tzu Ching
AU - Savitz, Sean I.
N1 - © 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
PY - 2021/4
Y1 - 2021/4
N2 - Objective: To review the global impact of the COVID-19 pandemic on stroke care-metrics and report data from a health system in Houston. Methods: We performed a meta-analysis of the published literature reporting stroke admissions, intracerebral hemorrhage (ICH) cases, number of thrombolysis (tPA) and thrombectomy (MT) cases, and time metrics (door to needle, DTN; and door to groin time, DTG) during the pandemic compared to prepandemic period. Within our hospital system, between January–June 2019 and January–June 2020, we compared the proportion of stroke admissions and door to tPA and MT times. Results: A total of 32,640 stroke admissions from 29 studies were assessed. Compared to prepandemic period, the mean ratio of stroke admissions during the pandemic was 70.78% [95% CI, 65.02%, 76.54%], ICH cases was 83.10% [95% CI, 71.01%, 95.17%], tPA cases was 81.74% [95% CI, 72.33%, 91.16%], and MT cases was 88.63% [95% CI, 74.12%, 103.13%], whereas DTN time was 104.48% [95% CI, 95.52%, 113.44%] and DTG was 104.30% [95% CI, 81.99%, 126.61%]. In Houston, a total of 4808 cases were assessed. There was an initial drop of ~30% in cases at the pandemic onset. Compared to 2019, there was a significant reduction in mild strokes (NIHSS 1-5) [N (%), 891 (43) vs 635 (40), P = 0.02]. There were similar mean (SD) (mins) DTN [44 (17) vs 42 (17), P = 0.14] but significantly prolonged DTG times [94 (15) vs 85 (20), P = 0.005] in 2020. Interpretation: The COVID-19 pandemic led to a global reduction in stroke admissions and treatment interventions and prolonged treatment time metrics.
AB - Objective: To review the global impact of the COVID-19 pandemic on stroke care-metrics and report data from a health system in Houston. Methods: We performed a meta-analysis of the published literature reporting stroke admissions, intracerebral hemorrhage (ICH) cases, number of thrombolysis (tPA) and thrombectomy (MT) cases, and time metrics (door to needle, DTN; and door to groin time, DTG) during the pandemic compared to prepandemic period. Within our hospital system, between January–June 2019 and January–June 2020, we compared the proportion of stroke admissions and door to tPA and MT times. Results: A total of 32,640 stroke admissions from 29 studies were assessed. Compared to prepandemic period, the mean ratio of stroke admissions during the pandemic was 70.78% [95% CI, 65.02%, 76.54%], ICH cases was 83.10% [95% CI, 71.01%, 95.17%], tPA cases was 81.74% [95% CI, 72.33%, 91.16%], and MT cases was 88.63% [95% CI, 74.12%, 103.13%], whereas DTN time was 104.48% [95% CI, 95.52%, 113.44%] and DTG was 104.30% [95% CI, 81.99%, 126.61%]. In Houston, a total of 4808 cases were assessed. There was an initial drop of ~30% in cases at the pandemic onset. Compared to 2019, there was a significant reduction in mild strokes (NIHSS 1-5) [N (%), 891 (43) vs 635 (40), P = 0.02]. There were similar mean (SD) (mins) DTN [44 (17) vs 42 (17), P = 0.14] but significantly prolonged DTG times [94 (15) vs 85 (20), P = 0.005] in 2020. Interpretation: The COVID-19 pandemic led to a global reduction in stroke admissions and treatment interventions and prolonged treatment time metrics.
KW - Brain Ischemia/epidemiology
KW - COVID-19/epidemiology
KW - Fibrinolytic Agents/administration & dosage
KW - Humans
KW - Pandemics
KW - Patient Admission/trends
KW - Stroke/epidemiology
KW - Texas/epidemiology
KW - Thrombectomy/trends
KW - Thrombolytic Therapy/trends
UR - http://www.scopus.com/inward/record.url?scp=85101250499&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101250499&partnerID=8YFLogxK
U2 - 10.1002/acn3.51322
DO - 10.1002/acn3.51322
M3 - Article
C2 - 33616305
AN - SCOPUS:85101250499
SN - 2328-9503
VL - 8
SP - 929
EP - 937
JO - Annals of Clinical and Translational Neurology
JF - Annals of Clinical and Translational Neurology
IS - 4
ER -